Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.

Matteo MonamiBesmir NreuAlessia ScatenaBarbara CresciFrancesco AndreozziGiorgio SestiEdoardo Mannucci

Published in: Diabetes, obesity & metabolism (2017)

Presently available data confirm the safety of GLP-1 receptor agonists for pancreatitis. Conversely, therapy with those drugs is associated with an increased risk of cholelithiasis, which deserves further investigation.

Keyphrases

electronic health record
randomized controlled trial
big data
systematic review
clinical trial
mesenchymal stem cells
study protocol
cell therapy
replacement therapy
double blind